GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

plonmarlimab   Click here for help

GtoPdb Ligand ID: 11644

Synonyms: TJ 003234 | TJ003234 | TJM2
Immunopharmacology Ligand
Compound class: Antibody
Comment: Plonmarlimab (TJM2/TJ003234) is a humanized IgG1 monoclonal antibody that is designed to neutralise granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) cytokine activity. It was developed by I-Mab Biopharma for potential to treat autoimmune diseases, and is likely to be Hu23F4-27 as claimed in I-Mab patent WO2018050111A1 [2].

COVID-19: Plonmarlimab is being evaluated as a mechanism to down-regulate elevated inflammation/cytokine release syndrome in patients with COVID-19 [1] in a Phase 2/3 study.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
GM-CSF Primary target of this compound Hs Antibody Binding 10.0 pKd - 2
⤷ pKd 10.0 (Kd 1x10-10 M) [2]
Description: Binding of clone Hu23F4-27 to hGM-CSF